Miguel Regueiro1, Benjamin Click2, Alyce Anderson3, William Shrank4, Jane Kogan4, Sandra McAnallen4, Eva Szigethy5. 1. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: regueiromd@gmail.com. 2. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 4. Center for High-Value Health Care, Insurance Services Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 5. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND & AIMS: Specialty medical homes (SMHs) are a new health care model in which a multidisciplinary team and specialists manage patients with chronic diseases. As part of a large integrated payer-provider network, we formed an inflammatory bowel diseases (IBDs) SMH and investigated its effects on health care use, disease activity, and quality of life (QoL). METHODS: We performed a retrospective analysis of 322 patients (58% female; mean age, 34.6 y; 62% with Crohn's disease; 32% with prior IBD surgery) enrolled in an IBD SMH, in conjunction with the University of Pittsburgh Medical Center Health Plan, from June 2015 through July 2016. Patients had at least 1 year of follow up. We evaluated changes in numbers of emergency department visits and hospitalizations from the year before vs after SMH enrollment. Secondary measures included IBD activity assessments and QoL. RESULTS: Compared to the year before IBD SMH enrollment, patients had a 47.3% reduction in emergency department visits (P < .0001) and a 35.9% reduction in hospitalizations (P = .008). In the year following IBD SMH enrollment, patients had significant reductions in the median Harvey-Bradshaw Index score (reduced from 4 to 3.5; P = .002), and median ulcerative colitis activity index score (from 4 to 3; P = .0003), and increases in QoL (median short inflammatory bowel disease questionnaire score increased from 50 to 51.8; P < .0001). Patients in the most extreme (highest and lowest) quartiles had the most improvement when we compared scores at baseline vs after enrollment. Based on multivariable regression analysis, use of corticosteroids (odds ratio [OR], 2.72; 95% CI, 1.32-5.66; P = .007) or opioids (OR, 3.20; 95% CI, 1.32-7.78; P = .01), and low QoL (OR, 4.44; 95% CI, 1.08-18.250; P = .04) at enrollment were significantly associated with persistent emergency department visits and hospitalizations. CONCLUSIONS: We found development of an IBD SMH to be feasible and significantly reduce unplanned care and disease activity and increase patient QoL 1 year after enrollment.
BACKGROUND & AIMS: Specialty medical homes (SMHs) are a new health care model in which a multidisciplinary team and specialists manage patients with chronic diseases. As part of a large integrated payer-provider network, we formed an inflammatory bowel diseases (IBDs) SMH and investigated its effects on health care use, disease activity, and quality of life (QoL). METHODS: We performed a retrospective analysis of 322 patients (58% female; mean age, 34.6 y; 62% with Crohn's disease; 32% with prior IBD surgery) enrolled in an IBDSMH, in conjunction with the University of Pittsburgh Medical Center Health Plan, from June 2015 through July 2016. Patients had at least 1 year of follow up. We evaluated changes in numbers of emergency department visits and hospitalizations from the year before vs after SMH enrollment. Secondary measures included IBD activity assessments and QoL. RESULTS: Compared to the year before IBDSMH enrollment, patients had a 47.3% reduction in emergency department visits (P < .0001) and a 35.9% reduction in hospitalizations (P = .008). In the year following IBDSMH enrollment, patients had significant reductions in the median Harvey-Bradshaw Index score (reduced from 4 to 3.5; P = .002), and median ulcerative colitis activity index score (from 4 to 3; P = .0003), and increases in QoL (median short inflammatory bowel disease questionnaire score increased from 50 to 51.8; P < .0001). Patients in the most extreme (highest and lowest) quartiles had the most improvement when we compared scores at baseline vs after enrollment. Based on multivariable regression analysis, use of corticosteroids (odds ratio [OR], 2.72; 95% CI, 1.32-5.66; P = .007) or opioids (OR, 3.20; 95% CI, 1.32-7.78; P = .01), and low QoL (OR, 4.44; 95% CI, 1.08-18.250; P = .04) at enrollment were significantly associated with persistent emergency department visits and hospitalizations. CONCLUSIONS: We found development of an IBDSMH to be feasible and significantly reduce unplanned care and disease activity and increase patient QoL 1 year after enrollment.
Authors: Julajak Limsrivilai; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Wen Huang; Peter D R Higgins Journal: Clin Gastroenterol Hepatol Date: 2016-09-17 Impact factor: 11.382
Authors: Eva M Szigethy; John I Allen; Marci Reiss; Wendy Cohen; Lilani P Perera; Lili Brillstein; Raymond K Cross; David A Schwartz; Lawrence R Kosinski; Joshua B Colton; Elizabeth LaRusso; Ashish Atreja; Miguel D Regueiro Journal: Clin Gastroenterol Hepatol Date: 2017-03-12 Impact factor: 11.382
Authors: Glynis Byrne; Greg Rosenfeld; Yvette Leung; Hong Qian; Julia Raudzus; Carlos Nunez; Brian Bressler Journal: Can J Gastroenterol Hepatol Date: 2017-10-18
Authors: Edward L Barnes; Yue Jiang; Michael D Kappelman; Millie D Long; Robert S Sandler; Alan C Kinlaw; Hans H Herfarth Journal: Inflamm Bowel Dis Date: 2020-07-17 Impact factor: 5.325
Authors: Jeffrey A Berinstein; Shirley A Cohen-Mekelburg; Gillian M Greenberg; Daniel Wray; Sameer K Berry; Sameer D Saini; A Mark Fendrick; Megan A Adams; Akbar K Waljee; Peter D R Higgins Journal: Clin Gastroenterol Hepatol Date: 2021-08-28 Impact factor: 13.576
Authors: Nisha B Shah; Jennifer Haydek; James Slaughter; Jonathan R Ashton; Autumn D Zuckerman; Rochelle Wong; Francesca Raffa; Ailish Garrett; Caroline Duley; Kim Annis; Julianne Wagnon; Lawrence Gaines; Robin Dalal; Elizabeth Scoville; Dawn B Beaulieu; David Schwartz; Sara N Horst Journal: Inflamm Bowel Dis Date: 2020-01-06 Impact factor: 5.325